Stock 2268 WUXI XDC CAYMAN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company WuXi XDC Cayman Inc.

Equities

2268

KYG9808A1058

Pharmaceuticals

End-of-day quote Hong Kong S.E.
Other stock markets
 06:00:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
19.06 USD +0.63% Intraday chart for WuXi XDC Cayman Inc. -17.31% -40.44%
10:13am WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling DJ
May. 01 WuXi XDC Cayman’s Profit Up 82% in 2023 MT

Business Summary

WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.

Number of employees: 1,178

Sales per Business

HKD in Million2022Weight2023Weight Delta
Fee-for-Service Basis
95.7 %
1,133 98.4 % 2,247 95.7 % +98.26%
Full-time Equivalent Basis
4.3 %
19 1.6 % 100 4.3 % +438.96%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
40.0 %
659 57.2 % 938 40.0 % +42.43%
North America
34.2 %
302 26.2 % 802 34.2 % +165.86%
Europe
21.7 %
150 13.0 % 508 21.7 % +239.65%
Rest of the World
4.2 %
42 3.6 % 98 4.2 % +135.89%

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,197,604,500 185,794,622 ( 15.51 %) 0 15.51 %

Shareholders

NameEquities%Valuation
WUXI APPTEC CO., LTD.
50.10 %
600,000,000 50.10 % 1 403 M $
Invesco Advisers, Inc.
3.170 %
37,970,000 3.170 % 89 M $
General Atlantic LLC
1.585 %
18,985,000 1.585 % 44 M $
Qatar Holding LLC
1.427 %
17,086,500 1.427 % 40 M $
UBS Asset Management (Singapore) Ltd.
1.268 %
15,188,000 1.268 % 36 M $
UBS Asset Management (Hong Kong) Ltd.
1.261 %
15,097,191 1.261 % 35 M $
Novo Holdings A/S (Investment Company)
0.7926 %
9,492,500 0.7926 % 22 M $
Fidelity Management & Research (Hong Kong) Ltd.
0.7256 %
8,689,583 0.7256 % 20 M $
Harvest Global Investments Ltd.
0.0248 %
296,838 0.0248 % 694 073 $
Nikko Asset Management Asia Ltd.
0.0114 %
136,975 0.0114 % 320 278 $

Company contact information

WuXi XDC Cayman, Inc.

No. 11 Xinhui Ring Road Xinwu District

, Wuxi City

+

http://www.wuxixdc.com
address WuXi XDC Cayman Inc.(2268)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
17.62 CNY
Average target price
28.8 CNY
Spread / Average Target
+63.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
WUXI XDC CAYMAN INC. Stock WuXi XDC Cayman Inc.
-40.44% 2.87B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.57% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.43% 240B
NOVARTIS AG Stock Novartis AG
+9.60% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.24% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 2268 Stock
  4. Company WuXi XDC Cayman Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW